SEOM-GEICO clinical guidelines on endometrial cancer (2021)

被引：0
作者：
María Pilar Barretina-Ginesta
María Quindós
Jesús Damián Alarcón
Carmen Esteban
Lydia Gaba
César Gómez
José Alejandro Pérez Fidalgo
Ignacio Romero
Ana Santaballa
María Jesús Rubio-Pérez
机构：
[1] Institut Català d’Oncologia (ICO),Medical Oncology Department
[2] Department of Medical Sciences,Medical Oncology Department
[3] Girona Biomedical Research Institute (IDIBGI). Department of Medical Sciences,Medical Oncology Department
[4] Medical School University of Girona (UdG),Medical Oncology Department
[5] Complexo Hospitalario Universitario de A Coruña. Biomedical Research Institute (INIBIC),Medical Oncology Department, Hospital Clínic of Barcelona, Therapeutics in Solid Tumors
[6] Hospital Universitari Son Espases,Department of Medical Oncology, Infanta Sofía and Henares Hospitals Foundation for Biomedical Research and Innovation (FIIB HUIS HHEN)
[7] Fundació Institut d’Investigació Sanitària Illes Balears (IdISBa),Medical Oncology Department
[8] Complejo Hospitalario de Toledo,Department of Medical Oncology
[9] Translational Genomic and Targeted,Medical Oncology Department
[10] Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),Medical Oncology Department
[11] Infanta Sofía University Hospital,undefined
[12] Hospital Clínico Universitario of Valencia. Biomedical Research Institute INCLIVA. CIBERONC,undefined
[13] Fundación Instituto Valenciano de Oncología (IVO),undefined
[14] Hospital Universitari i Politècnic La Fe,undefined
[15] Hospital Universitario Reina Sofía. University of Córdoba,undefined
来源：
Clinical and Translational Oncology | 2022年 / 24卷
关键词：
Endometrial cancer; Guideline; Diagnosis; Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Endometrial cancer (EC) is the second most common gynecological malignancy worldwide, the first in developed countries [Sung et al. in CA Cancer J Clin 71:209–249, 2021]. Although a majority is diagnosed at an early stage with a low risk of relapse, an important proportion of patients will relapse. Better knowledge of molecular abnormalities is crucial to identify high-risk groups in early stages as well as for recurrent or metastatic disease for whom adjuvant treatment must be personalized. The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of EC, and to provide evidence-based recommendations for clinical practice.
引用
收藏
页码：625 / 634
页数：9
相关论文
共 211 条
[21]  
Dörk T(2009)A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study Lancet 373 125-878
[22]  
Hillemanns P(2017)Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis Lancet Oncol 18 384-823
[23]  
Tempfer C(2010)Fertility-preserving treatment in young women with grade 1 presumed stage IA endometrial adenocarcinoma: a meta-analysis Gynecol Oncol 118 14-1255
[24]  
Breu J(2018)Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study Int J Gynecol Cancer 28 385-271
[25]  
Fleisch MC(2009)Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of highintermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial Int J Gynecol Cancer 19 873-233
[26]  
Smith ES(2010)External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma—a prospective randomized study Lancet 375 816-2431
[27]  
Da Cruz PA(2012)Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial Int J Radiat Oncol Biol Phys 82 1249-309
[28]  
Cadoo KA(2006)Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese gynecologic oncology group study Br J Cancer 95 266-3397
[29]  
Abu-Rustum NR(2008)Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies Gynecol Oncol 108 226-2326
[30]  
Pei X(2010)Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial Eur J Cancer 46 2422-1818
12345678910